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Abstract
Objective: To study the role of recombinant human LH supplementation in women with hypo-response to ovarian
stimulation.
Methods: We performed a systematic review and meta-analysis of prospective clinical trials in which recombinant
FSH monotherapy protocols were compared with LH-supplemented protocols in hypo-responders. A search was
conducted of the Scopus, MEDLINE databases without time or language restrictions. Primary outcome was clinical
pregnancy rate.
Results: Significantly higher clinical pregnancy rates (odds ratio: 2.03, P = 0.003), implantation rates (odds ratio: 2.62,
P = 0.004) and number of oocytes retrieved (weight mean differences: 1.98, P = 0.03) were observed in hypo-responders
supplemented with recombinant LH versus hypo-responders who underwent FSH monotherapy. No differences in
terms of mature oocytes or miscarriage rates were found between the two groups.
Conclusion: In conclusion, our analysis confirms that women with a hypo-response to exogenous gonadotropins
might benefit from LH supplementation. However, more trials are required before a definitive conclusion can be
drawn.
Keywords: LH, Recombinant LH, Hypo-responders, Assisted reproductive technologies, In vitro fertilization, Ovulation
induction
Introduction
An appropriate ovarian response to controlled ovarian
stimulation (COS) is crucial for the success of assisted
reproductive technologies (ART) [1]. The number of oo-
cytes retrieved at the end of stimulation is the parameter
most often used to assess ovarian response to exogenous
gonadotropin and is strictly related to live birth rate [2].
Based on ovarian biomarkers and oocyte number,
women are classically defined as poor, normal or
hyper-responders [1, 3]. However, there is a specific sub-
group of women termed “hypo-responders” who have an
unexpectedly poor or suboptimal response to gonado-
tropin therapy despite adequate ovarian pre-stimulation
parameters [4, 5].
Hypo-responders are hyposensitive to standard age,
ovarian biomarkers, and BMI-matched doses of exogen-
ous FSH [4–6]. This ovarian resistance to gonadotropin
stimulation might clinically manifest as an “initial slow
response” [7, 8] or be retrospectively diagnosed in
women who require higher-than-expected doses of go-
nadotropins on the basis of age, BMI, and ovarian re-
serve [9]. The hypo-responder patient differs from the
classic poor responder patient in at least two aspects.
First, in hypo-responders, the number of oocytes is re-
trieved is higher than three, albeit at the expense of ele-
vated gonadotropin consumption, whereas in classic
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poor responders, the number of oocytes retrieved is usu-
ally lower irrespective of the amount of gonadotropin
administered. Second, hypo-responders have normal
ovarian reserve tests (i.e., anti-Müllerian hormone and
antral follicle count), which are usually deranged in
women with the classic poor ovarian response.
The reasons for the hypo-responsiveness to gonado-
tropin stimulation are not entirely understood, but it has
been suggested that genetic mutations or single nucleotide
polymorphisms (SNPs) of gonadotropins and their recep-
tors might influence ovarian sensitivity to exogenous
gonadotropins [6, 10–12]. Hypo-responders undergoing
ART treatments might face increased treatment costs,
decreased cumulative live birth rates, and increased time
to live birth, suggesting a negative impact on fertility. Yet,
is still unclear how to most optimally manage this group
of patients, although recent evidence suggests that
hypo-responders might benefit from recombinant LH
(rLH) supplementation during ovarian stimulation [13–
15]. Physiologically, LH activity is crucial for proper
folliculogenesis. Indeed, in the late follicular phase,
granulosa cells are receptive to LH which can sustain
follicular growth even when exogenous FSH administra-
tion is discontinued [16]. While the indiscriminate use
of LH supplementation remains equivocal in normal
responders, who are characterized by a normal function
of the gonadal axis, the addition of LH supplementation
in hypo-responders may be clinically beneficial as these
patients can harbor polygenic traits affecting the func-
tional properties of endogenous gonadotropins and/or
their receptors [11]. To verify these preliminary obser-
vations, we aggregated the available published data of
prospective clinical trials on the effect of rLH supple-
mentation in hypo-responders using meta-analysis. Our
aim was to summarize the evidence on the clinical util-
ity of adding rLH to COS in hypo-responders undergo-
ing ART.
Methods
Search strategy
We conducted a systematic search using Medline/PubMed
and Scopus databases to identify all relevant studies. The
search terms used, alone or combined, were “luteinizing
hormone”, “recombinant LH”, “rLH”, “rhLH”, “ovulation
induction”, “assisted reproductive technology”, “ART”,
“in vitro fertilization”, “IVF”, “steady response”, “hypore-
sponse” (Additional file 1: Table S1). Hand searches of
relevant review articles and reference lists were carried
out. No time restriction and language restriction were
applied and the end date for all searches was March 2018.
Eligibility and data extraction
We included only prospective clinical trials in which re-
combinant human FSH (rFSH) alone protocols were
compared with rFSH + rLH supplementation in women
undergoing IVF/ICSI with a hypo-response to exogenous
rFSH monotherapy. Hypo-response was defined according
to authors’ criteria of included studies provided they met
with our inclusion criteria. Specifically, hypo-responders
were normogonadotropic women who required an ele-
vated total dose of rFSH (> 2500 IU) to obtain an adequate
number of oocytes retrieved or who had a plateau on
follicular growth with no or only marginal increase in
the estradiol level and in the follicular size during
stimulation. Data extraction was performed independ-
ently by three authors (IS, PD and AF) using prede-
fined data fields.
Outcome measures
The primary outcome was clinical pregnancy rate (de-
fined as the number of clinical pregnancies, i.e., presence
of one or more gestational sacs with foetal heart beat
seen at ultrasound examination at 6–8 weeks, expressed
per started cycle. Secondary outcomes were the number
of oocytes retrieved and number of metaphase II (MII)
oocytes, implantation rate (defined as the number of
gestational sacs observed divided by the number of em-
bryos transferred), and live birth rate (defined as the
number of deliveries per started cycles).
Protocol
This study was exempt from institutional review board
approval because it did not involve any human interven-
tion. We adhered to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines [17].
Study selection
First, the titles and abstracts of all articles were screened.
Duplications were removed using both Endnote online
software and manually. Disagreements were resolved by
discussion among authors. The full texts of eligible articles
published were subsequently obtained. The grey literature,
namely, unpublished studies and those published outside
widely available journals, case reports, conference pro-
ceedings, doctoral theses, dissertations, etc., was not con-
sidered [18] (Additional file 1: Table S1).
Bias assessment
Three authors (IS, PD and AF) independently assessed
the risk of bias of the studies eligible for the review
using the checklist created by the Cochrane Menstrual
Disorders and Subfertility Group [19]. The quality of
allocation concealment was graded as adequate (A), un-
clear (B) or inadequate (C). Non-randomized trials were
assessed using the Newcastle–Ottawa Scale (NOS) and
each study was judged on three issues: selection of the
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study group, comparability between groups, and ascer-
tainment of exposed and non-exposed cohorts [20].
Risk of bias across the studies was assessed by mul-
tiple analyses (Additional file 2: Table S2). Funnel
plots of the primary outcome were evaluated both
visually and formally with the ‘trim and fill’ method
and the Egger test [21, 22].
Quantitative analysis
Statistical analysis was carried out using Review Man-
ager 5.3 (The Nordic Cochrane Centre, The Cochrane
Collaboration). Categorical data were combined with a
pooled odds ratio (OR) using the Mantel-Haenszel
method. Continuous data were combined with weight
mean differences (WMD) using the inverse variance
method. The meta-analysis was conducted using the
fixed-effect-model (FEM) or the random effect model
(REM). REM was used in case of significant heterogen-
eity among studies. Heterogeneity was assessed using
the percentage of total variation in the estimated effect
across studies (I2). An I2 value > 50% indicates substan-
tial heterogeneity. P values < 0.05 were considered statis-
tically significant.
Subgroup and sensitivity analysis
Subgroup analyses were carried out by study type, namely,
randomized controlled trials and non-randomized con-
trolled trials to identify potential sources of heterogeneity.
Sensitivity analysis was carried out to assess the leverage
of studies judged to be at high risk of bias (Additional
file 3: Table S3). In detail, the risk of bias was evaluated
considering the following issues: study design; imprecision
(effect size with wide confidence interval), concerns
regarding random sequence generation and allocation
concealment.
Results
Study selection and characteristics
A total of 5906 items were identified in the Medline/
PubMed (N = 3670) and Scopus databases (n = 2236)
(Fig. 1). Duplications were removed by Endnote Online
(N = 368). Abstracts and titles (N = 5538) were reviewed
by two authors (AC, FC). Disagreements were resolved
by discussion with senior authors (CA, SE, GD).
Twenty-five full-text papers were assessed for eligibility.
Twenty studies were excluded because they did not
fulfill the inclusion criteria [23–42] (Additional file 4:
Fig. 1 Study flow chart according to PRISMA guidelines
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Table S4). Five studies met the inclusion criteria and
were included in our review. The characteristics of the
studies and the risk of bias are reported in Table 1 and
Additional file 2: Table S2.
Summary of results
Clinical pregnancy rate
Clinical pregnancy rates were investigated in three RCTs
[7–9] and in one cohort study [43] for a total of 361
participants (Fig. 2). The clinical pregnancy rate was
significantly higher in the rFSH plus rLH group than in
the rFSH alone group (OR 2.03, 95% CI 1.27–3.25, P =
0.003). The consistency in the direction of the effect,
and the overlap in confidence intervals across studies in-
creases confidence in the results. Sensitivity analysis in-
dicated that removing the papers that were considered
to have a high risk of bias [9, 43] did not affect the
pooled effect size.
Number of oocytes retrieved
Two RCTs [7, 8] and one cohort study [43], for a total
of 319 participants, were analyzed (Fig. 3). The estimated
pooled increase in the number of oocytes retrieved was
1.98 (WMD 1.98, 95% CI 0.17 to 3.80, I2 = 78%; P =
0.03), thus indicating a positive association between the
use of rLH supplementation and number of oocyte re-
trieved in hypo-responders. To assess the cause of the
heterogeneity, subgroup analysis was performed accord-
ing to by study type. Heterogeneity was reduced to 0%
in the RCT studies, suggesting that the difference be-
tween studies is explained by study type. The observed
pooled effect size was larger for RCTs, with a higher
number of oocytes retrieved compared to non-RCT (P =
003; Fig. 3). Sensitivity analysis indicated that removal of
the study that had a high risk of bias [43] had no mater-
ial effect on the results.
Number of metaphase II oocytes
Two RCTs [7, 9] and one cohort study [43], for a
total of 257 subjects, were pooled. Additional file 5:
Figure S1). Overall, no significant difference was ob-
served between patients stimulated with rFSH + rLH
and those with rFSH monotherapy in terms of num-
ber of MII oocytes retrieved (WMD 0.61, 95% CI
-2.08 to 3.31; I2 = 90%). In subgroup analysis, the
study type did not explain the heterogeneity between
studies. Sensitivity analysis indicated that removal of
the study with a high risk of bias [43] did not affect
the pooled effect estimates.
Implantation rates
Four RCTs [7–9, 44] and one cohort study [43] for a
total of 766 subjects, were analyzed (Fig. 4). The esti-
mated pooled increase in implantation rates was 2.62
(95% CI OR 1.37–4.99, I2 = 52%, P = 0.004) favoring the
rFSH + rLH group versus the rFSH alone group. The
heterogeneity estimates were not materially affected by
performing analyses separately by study type. However,
heterogeneity in low risk of bias studies was reduced to
40% compared to 52% in the overall analysis (Additional
file 3: Table S3), which suggests that some of the differ-
ences between studies are explained by study quality.
These results are therefore consistent in suggesting a
positive association between rLH supplementation and
implantation rates, but they also indicate the need for
additional studies to confirm the size of this association.
Sensitivity analysis indicated that removal of studies with
a high risk of bias [43, 44] did not affect the pooled
effect estimates.
Live birth rates
Live birth rates were investigated in only one RCT [8].
As shown in Additional file 6: Figure S2, live birth rates
were significantly higher in the rFSH + rLH group than
in the rFSH alone group (OR 2.44, 95% CI 1.03–2.77,
P = 0.04).
Miscarriage rate
Two RCTs [7, 8] and one cohort study [43] for a total of
319 participants, were pooled in this meta-analysis
(Additional file 7: Figure S3). Overall, there was no
significant difference in the estimated pooled miscarriage
rate between patients stimulated with rFSH + rLH and
patients on rFSH monotherapy (OR 1.01, 95% CI 0.52–
1.99; I2 = 0%). Subgroup analysis demonstrated that
study type had no material effect on the results. Simi-
larly, sensitivity analyses showed that the removal of the
study with a high risk of bias [43] did not affect the
pooled effect size.
Risk of bias across studies
The risk of a significant bias across studies regarding the
primary outcome (clinical pregnancy rate) was excluded
by Egger’s test (P = 0.642), which is confirmed by visual
inspection of the funnel plots and the trim and fill
method (Additional file 8: Figure S4).
Discussion
Summary of evidence
This meta-analysis indicates that women with ovarian
resistance to exogenous gonadotropin who undergo
COS for ART, the so-called “hypo-responders”, might
benefit from rLH supplementation. The use of rLH sup-
plementation was associated with increased clinical
pregnancy, number of oocytes retrieved, and implant-
ation rates, whereas no effect was noted concerning the
number of MII oocytes and risk of miscarriage. The ef-
fect on live birth was less clear as to date, only one trial
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has reported LBRs in hypo-responders co-treated with
rLH versus rFSH monotherapy during COS [8].
Interpretation of results and clinical considerations
The concept of hypo-response to exogenous gonadotropin
was introduced over a decade ago to describe women who
have an impaired response to ovarian stimulation [5, 45,
46]. These normo-ovulatory and normo-gonadotropic
women differ from classical poor responders in the sense
that they are usually younger and have a normal
age-matched ovarian reserve [13]. This ovarian resistance
can clinically manifest as an “initial slow response” or
“stagnation” in follicle growth during ovarian stimulation
with FSH monotherapy [7, 8]. In particular, stagnation
was defined by an absence or only marginal growth of
both follicles and estradiol levels during OS. In other
cases, a hypo-response can be retrospectively diagnosed
in women who require higher-than-expected doses of
gonadotropins on the basis of age, BMI and ovarian re-
serve [9, 47]. The trends seen in this meta-analysis are
consistent with a beneficial effect of rLH supplementation
during ovarian stimulation.
The mechanism by which rLH exerts its beneficial
effect in hypo-responders is not fully understood. How-
ever, the fact that these patients and normal responders
to gonadotropin stimulation share similar phenotypic
characteristics suggests a genotype-based mechanism
[10, 12, 48–50]. In other words, these women might have
a peculiar genotype profile that could influence their re-
sponse to ovarian stimulation. Since hypo-responders
exhibit serum LH levels comparable to those of normal
responders, it has been hypothesized that either the en-
dogenous LH molecule or the LH receptor, or both, are
functionally deficient and, therefore, implicated in the
pathogenesis of hypo-response. Indeed, it has been re-
ported that patients with a less functional common LH β
chain variant have an increased resistance to gonadotropin
stimulation [11, 51]. Furthermore, preliminary data show
that even specific LH receptor polymorphisms could influ-
ence ovarian response during COS [52, 53]. In a previous
study, we found that the prevalence of hypo-response was
higher in carriers of the Serine variant of a common
FSH-R polymorphism than in wild-type haplotypes [54].
Polymorphism of the FSH-R promoter was also associated
with an impaired response to ovarian stimulation, i.e.,
higher consumption of exogenous gonadotropin in A
allele carriers than in G allele carriers [55, 56].
It is, therefore, biologically plausible that LH supple-
mentation in women with genetic polymorphisms
involving gonadotropins and their receptors might over-
come the genetically determined ovarian resistance to
gonadotropin stimulation. In line with this hypothesis,
Ramaraju et al. observed that both women heterozygous
or homozygous for the G allele required higher doses of
rLH supplementation during OS than those without
these genetic traits; in their study, the use of rLH sup-
plementation resulted in increased clinical pregnancy
rates [57]. The added LH during stimulation acts on
theca cells and increases androgen synthesis, which in
turn improve FSH receptor sensitivity during COS
[58–60]. This hypothesis should be verified in specific
trials and could be a fruitful research topic.
Fig. 2 Forest plot of odds ratio for the clinical pregnancy rate in rFSH + rLH versus rFSH alone treatment
Conforti et al. Reproductive Biology and Endocrinology           (2019) 17:18 Page 7 of 12
As for the type of LH activity, rLH seems to be as-
sociated with better outcomes in hypo-responders
than hMG. Indeed, a significantly lower implantation
rate was observed in hypo-responders treated with
hMG than with rLH [8]. This observation might be
explained by the differential effect of LH activity pro-
vided by LH and hCG-containing drugs on the endo-
metrium. Current evidence suggests that hCG (versus
rLH) might adversely affect the endometrial function
[61, 62]. Indeed, this phenomenon might explain why
ongoing pregnancy rates are higher in frozen embryo
transfer (FET) using natural cycles with spontaneous
LH surge compared to natural cycles with exogenous
hCG [63].
Additionally, there are differential biological activity
of these two molecules on granulosa cells. Recombin-
ant LH exerts both proliferative and antiapoptotic ac-
tions through phosphorylated extracellular-regulated
kinase 1/2 (pERK1/2) and phosphorylated AKT signals
[64]. By contrast, LH activity provided by hCG, con-
tained in hMG formulations, displays a steroidogenic
and proapoptotic effect mediated by cAMP and pro-
tein kinase A (PKA) [64]. These molecular differences
might translate in improved pregnancy success among
Fig. 3 Forest plot of weight mean difference for the number of oocytes retrieved in rFSH + rLH versus rFSH alone treatment
Fig. 4 Forest plot of odds ratio for implantation rate in rFSH + rLH versus rFSH alone treatment
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IVF patients treated with rLH rather than hMG, as
shown in a 2017 large meta-analysis [14].
Limitations and strengths
The main limitation of this study is the low number of
trials conducted thus far. Ovarian resistance to gonado-
tropin stimulation remains a largely undervalued issue
in the reproductive field. This may be because until re-
cently, most clinicians did not consider the issue of
hypo-responsiveness if the number of oocytes retrieved
after stimulation was consistent with women’s reproduction
potential and the antral follicle count at the beginning of
stimulation. Indeed, previous systematic reviews investi-
gated the role of rLH supplementation without distinguish-
ing hypo-response from other conditions such a poor
or normal response [19, 65]. In a 2014 meta-analysis
for a total of 1129 ART cycles in POR patients supple-
mented or not with rLH illustrates this phenomenon [66].
In fact, it was noted that more oocytes were retrieved in
rLH-supplemented cycles than with rFSH monotherapy
(12 studies, n = 1077; weighted mean difference + 0.75
oocytes; 95% CI 0.14–1.36). In that study, the use of rLH
supplementation also improved clinical pregnancy rates
(14 studies, n = 1179; relative risk [RR] 1.30; 95% confidence
interval [CI] 1.01–1.67; intention-to-treat population [ITT]
population). Nevertheless, a careful examination of the
included studies reveals that the beneficial effect of rLH
was more pronounced in studies involving hypo-responders
than in those with classic POR. The inclusion of
studies involving hypo-responders in the Lehert et
al. (2014) review thus explains the overall favorable
results observed with rLH supplementation in the
POR patient.
The merit of our review is that, albeit at the cost of a
low number of observations, it focused on prospective
clinical trials involving the specific subgroup of
hypo-responders. Moreover, the low heterogeneity among
trials utilized in our meta-analyzes concerning the primary
outcome provides evidence that the observed effect was
causal. Nevertheless, heterogeneity was high among most
secondary outcomes, which might be partially explained
by study type and quality, as the subgroup and sensitivity
analyses demonstrated. Furthermore, different protocols
and rLH dosages were used in the studies examined. It
was not possible to evaluate outcomes according to the
dosage and time of LH administration due to the low
number of studies. Only one trial demonstrated that 150
IU of rLH result in more oocytes retrieved and a higher
percentage of mature oocytes than do 75 IU in a long
GnRH agonist protocol [23]. Along the same lines, the ef-
fect of rLH supplementation in hypo-responders undergo-
ing OS with GnRH antagonists remains to be established,
as the trials included in this meta-analysis utilized pituit-
ary suppression with GnRH agonist. Despite the low
number of studies and high heterogeneity in some of the
outcome measures, there was no evidence of publication
bias. Furthermore, sensitivity analyses demonstrated min-
imal differences when studies with high risk of bias were
excluded, thus indicating our results are conservative.
Future research
Ovarian resistance to exogenous gonadotropin still rep-
resents an undervalued topic in the reproductive field.
There is a lack of a standardized definition and limited
knowledge about its pathophysiology mechanisms. Two
years ago, hypo-responsiveness to gonadotropin stimula-
tion was included in a novel stratification system, desig-
nated the POSEIDON criteria, for infertility patients
undergoing ART [4, 67, 68]. Novel markers that accur-
ately reflect the “dynamic” nature of follicular growth in
response to exogenous gonadotropin are under investi-
gation, an example being the follicle-to-oocytes index
(FOI), which is the ratio between the number of oocytes
retrieved and AFC at the beginning of stimulation [69].
A better understanding of the effect exerted by genetic
polymorphisms of gonadotropins and their receptors,
and subsequently COS outcomes, will help to improve
treatment and counseling for patients seeking ART.
Additional studies, in particular those that assess various
LH supplementation doses and regimes, including GnRH
antagonists and cumulative LBR as the main outcome
measure, are required. Such studies might increase the
precision of the estimated effect sizes, thus allowing better
appraisal of the clinical importance of our findings.
Conclusion
In conclusion, our analyses indicate that women with a
previous hypo-response to exogenous FSH stimulation
benefit from LH supplementation as a means of increas-
ing clinical pregnancy, implantation, and number of oo-
cytes retrieved. LH supplementation might be added
during COS on the same cycle to rescue an ongoing
hypo-response or in a subsequent cycle. Further research
is required to quantify the effect of LH supplementation
more precisely and to evaluate the clinical utility of LH
supplementation in hypo-responders using the GnRH
antagonist protocol.
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